Literature DB >> 12455052

Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.

Mariko Kawakami1, Koji Kawakami, Raj K Puri.   

Abstract

IL-13 cytotoxin, composed of IL-13 and a truncated form of Pseudomonas exotoxin, targets IL-13R-overexpressing tumor cell lines in vitro and in vivo. To reveal the molecular mechanism of IL-13 cytotoxin-induced cell death in vivo, we demonstrate activation of apoptotic pathways in 2 s.c. growing human SCCHN tumor models in immunodeficient mice after i.t. administration of IL-13 cytotoxin. Treatment of HN12 tumor bearing mice with i.p. or i.t. administration of IL-13 cytotoxin mediated marked regression of established tumors with complete remission. Interestingly, after a single i.t. administration, IL-13 cytotoxin disappeared within 6 hr but accumulation of caspase-3, -8 and -9 and cleavage of procaspase-3 and PARP continued within the tumors for a prolonged period. We further demonstrate that IL-13 cytotoxin also utilizes an alternate pathway of cell death via the release of cytochrome c from mitochondria to the cytosol. Our results indicate that IL-13 cytotoxin induces 2 major pathways of apoptosis, which may play a role in tumor regression. In addition, apoptotic molecules may serve as surrogate molecular markers of tumor response to IL-13R-directed cytotoxin therapy. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12455052     DOI: 10.1002/ijc.10778

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  5 in total

Review 1.  Glioblastoma antigen discovery--foundations for immunotherapy.

Authors:  Tej D Azad; Seyed-Mostafa Razavi; Benjamin Jin; Karen Lee; Gordon Li
Journal:  J Neurooncol       Date:  2015-06-05       Impact factor: 4.130

2.  Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

Authors:  Sandeep Kunwar; Susan Chang; Manfred Westphal; Michael Vogelbaum; John Sampson; Gene Barnett; Mark Shaffrey; Zvi Ram; Joseph Piepmeier; Michael Prados; David Croteau; Christoph Pedain; Pamela Leland; Syed R Husain; Bharat H Joshi; Raj K Puri
Journal:  Neuro Oncol       Date:  2010-02-04       Impact factor: 12.300

Review 3.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

4.  EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.

Authors:  Henrick Horita; Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Journal:  J Neurooncol       Date:  2009-05-17       Impact factor: 4.130

Review 5.  Current aspects of targeted therapy in head and neck tumors.

Authors:  Andreas Dietz; Andreas Boehm; Christian Mozet; Gunnar Wichmann; Athanassios Giannis
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-07       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.